NASDAQ: ALEC

Pfizer's TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk
CompanyDrug

Pfizer’s TUKYSA Wins FDA Approval for First‑Line Maintenance in HER2+ Metastatic Breast Cancer – Chemotherapy‑Free Tucatinib Combination Delivers 36% Reduction in Progression Risk

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved TUKYSA® (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with…

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World's First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

BMS Secures Conditional NMPA Approval for Zenbexus (Iberdomide) – World’s First Oral CELMoD Agent Wins China Landmark in Relapsed Multiple Myeloma

Roche's Fenebrutinib NDA Accepted for FDA Priority Review – Non‑Covalent BTK Inhibitor Targets Both RMS and PPMS in Landmark MS Filing

Roche’s Fenebrutinib NDA Accepted for FDA Priority Review – Non‑Covalent BTK Inhibitor Targets Both RMS and PPMS in Landmark MS Filing

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson's Disease
CompanyDeals

Alector Grants Genentech Worldwide Rights to AL050 in $1.27B Deal – Brain‑Penetrant GCase Therapy Targets Neurodegeneration in Parkinson’s Disease